文献速递头颈部肿瘤放疗放疗物理与技术

回旋加速器硼中子俘获治疗复发或局部晚期头颈癌的II期试验

Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial.
PubMed 文献 · Radiother Oncol · 2020-11-11

JHN002开放标签II期试验评估回旋加速器基超热中子源联合borofalan(10B)的硼中子俘获治疗(BNCT)用于复发或局部晚期头颈癌。入组8例复发鳞癌(R-SCC)和13例复发/局部晚期非鳞癌(R/LA-nSCC),客观缓解率(ORR)71%,R-SCC与R/LA-nSCC的2年总生存率分别为58%和100%,常见不良事件为脱发、高淀粉酶血症和恶心。

要点

  • BNCT对复发或局部晚期头颈癌ORR达71%,R-SCC完全缓解率50%。
  • R-SCC的2年中位无局部区域进展生存期(LRPFS)为11.5个月。
  • 常见不良事件为脱发95%、高淀粉酶血症86%、恶心81%。

核心结论

  • 回旋加速器基BNCT联合borofalan(10B)对复发或局部晚期头颈癌显示有前景的疗效。

研究设计与样本

  • 开放标签II期JHN002试验,入组8例R-SCC和13例R/LA-nSCC患者。
  • 静脉给予borofalan(10B)400 mg/kg后行中子照射,肿瘤剂量以黏膜最大剂量12 Gy-Eq被动确定。
  • 主要终点为客观缓解率(ORR),计划JHN002 Look Up研究评估LRPFS。

主要发现

  • 全部患者ORR为71%,R-SCC完全缓解/部分缓解为50%/25%,R/LA-nSCC为8%/62%。
  • R-SCC和R/LA-nSCC的2年总生存率分别为58%和100%。
  • R-SCC的中位LRPFS为11.5个月。
  • 常见不良事件包括脱发(95%)、高淀粉酶血症(86%)和恶心(81%)。

关键数值与推荐

  • 所有R-SCC患者既往接受过放疗,中位剂量65.5 Gy(范围59.4-76.0 Gy)。
  • 硼中子俘获治疗采用回旋加速器基超热中子源(C-BENS),borofalan(10B)剂量400 mg/kg。
  • 肿瘤剂量以黏膜最大剂量12 Gy-Eq被动确定。

临床怎么用

  • 对于既往放疗后复发或局部晚期的头颈癌,可考虑回旋加速器基BNCT作为治疗选择。
  • 治疗前需评估患者是否符合R-SCC或R/LA-nSCC,并注意黏膜最大剂量12 Gy-Eq的限制。
  • 应监测脱发、高淀粉酶血症和恶心等常见不良事件。

局限性

  • 单臂开放标签设计,缺乏随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Boron neutron capture therapy (BNCT) can be performed without reactors due to development of cyclotron-based epithermal neutron source (C-BENS), which is optimized for treatment for deeper-seated tumors. The purpose of this study was to evaluate efficacy and safety of cyclotron-based BNCT with borofalan (10B) for recurrent or locally advanced head and neck cancer. MATERIALS AND METHODS: In this open-label, phase II JHN002 trial of BNCT using C-BENS with borofalan (10B), patients with recurrent squamous cell carcinoma (R-SCC) or with recurrent/locally advanced non-squamous cell carcinoma (R/LA-nSCC) of the head and neck were intravenously administered 400 mg/kg borofalan (10B), followed by neutron irradiation. The tumor dose was determined passively as the mucosal maximum dose of 12 Gy-Eq. The primary endpoint was the objective response rate (ORR). Post-trial observational JHN002 Look Up study was planned for evaluating locoregional progression-free survival (LRPFS). RESULTS: Eight R-SCC and 13 R/LA-nSCC patients were enrolled. All R-SCC patients had prior radiotherapy with a median dose of 65.5 Gy (range, 59.4-76.0 Gy). The ORR for all patients was 71%, and complete response/partial response were 50%/25% in R-SCC and 8%/62% in R/LA-nSCC. The 2-year overall survival for R-SCC and R/LA-nSCC were 58% and 100%, respectively. The median LRPFS was 11.5 months for R-SCC. Frequently observed adverse events included alopecia (95%), hyperamylasemia (86%), and nausea (81%). CONCLUSION: These data suggest that BNCT using C-BENS with borofalan (10B) is a promising treatment option for patients with R-SCC or R/LA-nSCC of the head and neck.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 2020. PMID: 33186684. doi:10.1016/j.radonc.2020.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。